Table 1.

Amyloid deposition in mice treated with cobra venom factor

		Amyloid deposition
		Liver		Spleen
Treatment	Serum C3 on day 3*	125I-SAP retained†	Amyloid score‡	125I-SAP retained†	Amyloid score‡
None n=3	590 (40)	0·9 (0·2)	0	0·1 (0)	0
5 U CVF day −1 n=5	299 (78)	13·7 (9·5) P = 1·0000	2 (0–3) P = 0·2063	2·5 (2·2) P = 0·6349	3 (0–4) P=0·4444
Buffer day −1 n=5	>621§	15·6 (10·9)	3 (0–3)	3·7 (0·8)	4 (3–4)
20 U CVF day −1–day 3 n=5	″77 (12)	14·9 (3·9) P = 0·1508	1·5 (1–2) P = 0·07937	2·3 (0·5) P=0·1349	3 (3–3) P=0·04762
Buffer day −1–day 3 n=5	>621§	22·8 (8·8)	2 (2–3)	3·6 (1·6)	4 (3–5)

All mice, except those in the ‘None’ group above, received AEF and AgNO₃ on day 0 as described in Methods.

^*Mean (SD), mg/l.

^†Mean (SD),% injected dose of ¹²⁵ I-labelled human SAP retained in organs at death on day 3, after intravenous tracer injection on day 2.

^‡Median (range), histological grade of congophilic amyloid deposits assessed as in Methods.

^§C3 values in all mice exceeded assay upper limit and were not reassayed on dilution.

P-values are for Wilcoxon rank sum (Mann–Whitney) tests between CVF-treated and corresponding buffer-treated control groups.